Read the main articles published in the last three years, starting in 2018, signed by one or more of our experts:


July, 2021
An update on the pathogenesis of COVID-19 and supposedly rare thrombotic events after vaccination

June, 2021
Therapeutic versus prophylactic anticoagulation for hospital inpatients with COVID-19 and elevated D-dimer concentration: an open, multicenter, randomized, controlled trial

April, 2021
Randomized clinical trial to evaluate a routine complete anticoagulation strategy in patients with coronavirus infection (SARS-CoV2) admitted to the hospital: Rationale and design of Action (AntiCoagulation Coronavirus) – Phase 4


December, 2020

Comparative studies on the anticoagulant profile of branded enoxaparin and a new biosimilar version

December, 2020

Drug Interactions of 257 Antineoplastic Supportive Agents with 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms

December, 2020

Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020

December, 2020

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa

June, 2020

Rationale and design for the Apixaban versus ClopidoGRel study in an aspirin background in a patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial

Junho, 2020

Guidelines on diagnosis, prevention and treatment of thromboembolic complications at COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Committee on Thrombosis and Hemostasis of the Brazilian Association of Hematology, Hemotherapy and Cell Therapy


December, 2019

Oral anticoagulants and management of cancer-associated thrombosis. Where will we be in 2019?

December, 2019

Rivaroxaban plus aspirin for cardiovascular protection: Rationale for vascular dose and dual pathway inhibition

December, 2019

Porcine Mucosal Heparin Shortage Crisis! What Are the Options?

December, 2019

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

December, 2019

Zika and Chikungunya Virus and Risk for Venous Thromboembolism

October, 2019

Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?

May, 2019

Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial

May, 2019

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

February, 2019

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer


December, 2018

Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial

December, 2018

Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide

December, 2018

Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial

August, 2018

Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint

February, 2018

Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again?